Tony Mok, Md, The Chinese University of Hong Kong (CUHK), China
Final OS Data from the ALEX Study Revealed - Alectinib Brings New Hope for Long-Term Survival and Potential Clinical Cure in Advanced ALK-Positive NSCLC Patients! Unraveling the Evolution of First-Line Treatment Paradigms and Future Breakthrough Directions.